Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction

A Study to Evaluate Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction and Control Healthy Volunteers

The objective of the study is to compare the pharmacokinetics profiles and safety of Evogliptin in patients wit hepatic dysfunction versus healthy volunteers after single oral dose of Evogliptin

When the future evogliptin be administered to liver dysfunction patients, to investgate whether dose adjustment is necessary.

Inclusion Criteria:

<Hepatic Dysfunction>

• At least 6 months with chronic liver disease (Regardless of cause hepatic dysfunction)
• Child-Pugh A or B

<Healthy Control>

• Subject has the following conditions: age ± 5 years, BMI ± 20%, same sex of each matched hepatic dysfunction subject

Exclusion Criteria:

<Hepatic Dysfunction>

• Child-Pugh C
• History of Liver transplant

<Healthy Control>

• History of chronic liver disorders
• Pregnant or lactating women